ArticleActa pharmacologica Sinica2026
Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination.
Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs), a revolutionary tumor therapeutic modality integrating the targeting specificity of monoclonal antibodies and the cytotoxicity of payloads, have undergone four generations of development, with over 20 approved drugs and more than 300 candidates in clinical trials globally. Despite their remarkable success in treating both hematological malignancies and solid tumors, traditional ADCs still face intractable challenges, including heterogeneity in target antigen expression, insufficient internalization, payload-mediated drug resistance, and severe treatment-related adverse events. This review elaborates on the latest design optimization strategies and research advances of next-generation function-enhanced ADCs, focusing on four core directions: bispecific ADC construction, internalization efficiency improvement, binding affinity enhancement, and payload combination innovation.
Indexed as
Identifiers
42463920What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.